ABT
The long cleanup after the formula recall
Abbott is officially trying to move on from the 2022 infant formula saga. The company said it reached an agreement with the Department of Justice to resolve the government investigation and lawsuit, plus related cases from relators and state attorneys general tied to the recall at its Sturgis, Michigan plant.
The company’s message is basically: we’re settling, but we’re not confessing. Abbott says the settlement does not represent any finding of fault or liability, and it also points out that the government already closed its criminal investigation.
Why this matters for investors
This isn’t exactly a growth story, but it is a cleanup story. Legal overhangs can hang around like gum on your shoe, and this one has followed Abbott since the infant formula crisis blew up in 2022.
A few points that matter:
- It removes another layer of uncertainty from a headline risk investors have been forced to remember.
- It may help narrow the legal and reputational drag around the formula business.
- It doesn’t magically erase the recall history, but it does suggest Abbott is closer to putting the issue behind it.
The fine print, with less legalese
Abbott also said tests by government regulators on unopened product from the homes of infants under investigation were negative for Cronobacter sakazakii. The company adds that no unopened, distributed Abbott infant formulas have ever tested positive for the bacteria.
Big picture: this is Abbott paying to close a painful chapter, not a new business breakout. But for a big healthcare name, fewer legal landmines is still something the market tends to appreciate.